{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T20:11:13Z","timestamp":1772914273733,"version":"3.50.1"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s11102-023-01327-2","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T04:02:01Z","timestamp":1686801721000},"page":"281-287","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["An update on, and genetics of refractory adenomas of childhood"],"prefix":"10.1007","volume":"26","author":[{"given":"Constantine A.","family":"Stratakis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,15]]},"reference":[{"key":"1327_CR1","doi-asserted-by":"publisher","first-page":"4268","DOI":"10.1210\/jc.2010-0537","volume":"95","author":"A Raappana","year":"2010","unstructured":"Raappana A, Koivukangas J, Ebeling T, Pirila T (2010) Incidence of pituitary adenomas in Northern Finland in 1992\u20132007. J Clin Endocrinol Metab 95:4268\u20134275. https:\/\/doi.org\/10.1210\/jc.2010-0537","journal-title":"J Clin Endocrinol Metab"},{"key":"1327_CR2","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/cncr.20412","volume":"101","author":"S Ezzat","year":"2004","unstructured":"Ezzat S et al (2004) The prevalence of pituitary adenomas: a systematic review. Cancer 101:613\u2013619. https:\/\/doi.org\/10.1002\/cncr.20412","journal-title":"Cancer"},{"key":"1327_CR3","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1530\/EJE-15-0189","volume":"173","author":"TT Agustsson","year":"2015","unstructured":"Agustsson TT et al (2015) The epidemiology of pituitary adenomas in Iceland, 1955\u20132012: a nationwide population-based study. Eur J Endocrinol 173:655\u2013664. https:\/\/doi.org\/10.1530\/EJE-15-0189","journal-title":"Eur J Endocrinol"},{"key":"1327_CR4","doi-asserted-by":"publisher","first-page":"4769","DOI":"10.1210\/jc.2006-1668","volume":"91","author":"AF Daly","year":"2006","unstructured":"Daly AF et al (2006) High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 91:4769\u20134775. https:\/\/doi.org\/10.1210\/jc.2006-1668","journal-title":"J Clin Endocrinol Metab"},{"key":"1327_CR5","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1586\/14737175.8.4.563","volume":"8","author":"MF Keil","year":"2008","unstructured":"Keil MF, Stratakis CA (2008) Pituitary tumors in childhood: update of diagnosis, treatment and molecular genetics. Expert Rev Neurother 8:563\u2013574. https:\/\/doi.org\/10.1586\/14737175.8.4.563","journal-title":"Expert Rev Neurother"},{"key":"1327_CR6","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s11102-018-0872-8","volume":"21","author":"F Yoo","year":"2018","unstructured":"Yoo F, Kuan EC, Heaney AP, Bergsneider M, Wang MB (2018) Corticotrophic pituitary carcinoma with cervical metastases: case series and literature review. Pituitary 21:290\u2013301. https:\/\/doi.org\/10.1007\/s11102-018-0872-8","journal-title":"Pituitary"},{"key":"1327_CR7","volume-title":"Classifcation of tumours of endocrine organs","author":"WHO","year":"2017","unstructured":"WHO (2017) Classifcation of tumours of endocrine organs. IARC Publications, Lyon"},{"key":"1327_CR8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1159\/000371806","volume":"101","author":"E Chatzellis","year":"2015","unstructured":"Chatzellis E, Alexandraki KI, Androulakis II, Kaltsas G (2015) Aggressive pituitary tumors. Neuroendocrinology 101:87\u2013104. https:\/\/doi.org\/10.1159\/000371806","journal-title":"Neuroendocrinology"},{"key":"1327_CR9","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-17-0796","volume":"178","author":"G Raverot","year":"2018","unstructured":"Raverot G et al (2018) European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol 178:G1\u2013G24. https:\/\/doi.org\/10.1530\/EJE-17-0796","journal-title":"Eur J Endocrinol"},{"key":"1327_CR10","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00401-013-1084-y","volume":"126","author":"J Trouillas","year":"2013","unstructured":"Trouillas J et al (2013) A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol 126:123\u2013135. https:\/\/doi.org\/10.1007\/s00401-013-1084-y","journal-title":"Acta Neuropathol"},{"key":"1327_CR11","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1530\/EJE-17-0933","volume":"178","author":"A McCormack","year":"2018","unstructured":"McCormack A et al (2018) Treatment of aggressive pituitary tumours and carcinomas: results of a european Society of Endocrinology (ESE) survey 2016. Eur J Endocrinol 178:265\u2013276. https:\/\/doi.org\/10.1530\/EJE-17-0933","journal-title":"Eur J Endocrinol"},{"key":"1327_CR12","doi-asserted-by":"publisher","first-page":"C7","DOI":"10.1530\/EJE-18-0250","volume":"178","author":"J Trouillas","year":"2018","unstructured":"Trouillas J et al (2018) Aggressive pituitary tumours and carcinomas: two sides of the same coin? Eur J Endocrinol 178:C7\u2013C9. https:\/\/doi.org\/10.1530\/EJE-18-0250","journal-title":"Eur J Endocrinol"},{"key":"1327_CR13","doi-asserted-by":"publisher","first-page":"R213","DOI":"10.1530\/EJE-14-0013","volume":"170","author":"D Maiter","year":"2014","unstructured":"Maiter D, Delgrange E (2014) Therapy of endocrine disease: the challenges in managing giant prolactinomas. Eur J Endocrinol 170:R213\u2013227. https:\/\/doi.org\/10.1530\/EJE-14-0013","journal-title":"Eur J Endocrinol"},{"key":"1327_CR14","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3171\/jns.2002.97.2.0299","volume":"97","author":"RK Shrivastava","year":"2002","unstructured":"Shrivastava RK, Arginteanu MS, King WA, Post KD (2002) Giant prolactinomas: clinical management and long-term follow up. J Neurosurg 97:299\u2013306. https:\/\/doi.org\/10.3171\/jns.2002.97.2.0299","journal-title":"J Neurosurg"},{"key":"1327_CR15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1530\/EJE-13-0503","volume":"170","author":"E Delgrange","year":"2014","unstructured":"Delgrange E et al (2014) Giant prolactinomas in women. Eur J Endocrinol 170:31\u201338. https:\/\/doi.org\/10.1530\/EJE-13-0503","journal-title":"Eur J Endocrinol"},{"key":"1327_CR16","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1530\/EJE-09-0406","volume":"161","author":"JE Jennings","year":"2009","unstructured":"Jennings JE et al (2009) Aggressive pituitary adenomas occurring in young patients in a large polynesian kindred with a germline R271W mutation in the AIP gene. Eur J Endocrinol 161:799\u2013804. https:\/\/doi.org\/10.1530\/EJE-09-0406","journal-title":"Eur J Endocrinol"},{"key":"1327_CR17","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1159\/000479511","volume":"89","author":"LF de Castro","year":"2018","unstructured":"de Castro LF et al (2018) Beneficial Effects of high doses of Cabergoline in the treatment of Giant Prolactinoma resistant to dopamine agonists: a Case Report with a 21-Year Follow-Up. Horm Res Paediatr 89:63\u201370. https:\/\/doi.org\/10.1159\/000479511","journal-title":"Horm Res Paediatr"},{"key":"1327_CR18","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3171\/jns.2006.104.1.54","volume":"104","author":"ZB Wu","year":"2006","unstructured":"Wu ZB et al (2006) Bromocriptine treatment of invasive giant prolactinomas involving the cavernous sinus: results of a long-term follow up. J Neurosurg 104:54\u201361. https:\/\/doi.org\/10.3171\/jns.2006.104.1.54","journal-title":"J Neurosurg"},{"key":"1327_CR19","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1007\/s12020-018-1702-5","volume":"62","author":"HY Huang","year":"2018","unstructured":"Huang HY, Zhai W, Tang H, Hui GZ, Wu ZB (2018) Cabergoline for the treatment of bromocriptine-resistant invasive giant prolactinomas. Endocrine 62:464\u2013469. https:\/\/doi.org\/10.1007\/s12020-018-1702-5","journal-title":"Endocrine"},{"key":"1327_CR20","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s00381-006-0177-5","volume":"23","author":"P Semple","year":"2007","unstructured":"Semple P, Fieggen G, Parkes J, Levitt N (2007) Giant prolactinomas in adolescence: an uncommon cause of blindness. Childs Nerv Syst 23:213\u2013217. https:\/\/doi.org\/10.1007\/s00381-006-0177-5","journal-title":"Childs Nerv Syst"},{"key":"1327_CR21","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1210\/jc.2014-3670","volume":"100","author":"S Salenave","year":"2015","unstructured":"Salenave S et al (2015) Macroprolactinomas in children and adolescents: factors associated with the response to treatment in 77 patients. J Clin Endocrinol Metab 100:1177\u20131186. https:\/\/doi.org\/10.1210\/jc.2014-3670","journal-title":"J Clin Endocrinol Metab"},{"key":"1327_CR22","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3109\/02688699409002393","volume":"8","author":"RJ Cook","year":"1994","unstructured":"Cook RJ, Uttley D, Wilkins PR, Archer DJ, Bell BA (1994) Prolactinomas in men masquerading as invasive skull base tumours. Br J Neurosurg 8:51\u201355","journal-title":"Br J Neurosurg"},{"key":"1327_CR23","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1530\/eje.0.1510709","volume":"151","author":"M Rix","year":"2004","unstructured":"Rix M et al (2004) Cushing\u2019s disease in childhood as the first manifestation of multiple endocrine neoplasia syndrome type 1. Eur J Endocrinol 151:709\u2013715","journal-title":"Eur J Endocrinol"},{"key":"1327_CR24","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/cen.13796","volume":"89","author":"A Makri","year":"2018","unstructured":"Makri A et al (2018) Children with MEN1 gene mutations may present first (and at a young age) with cushing disease. Clin Endocrinol (Oxf) 89:437\u2013443. https:\/\/doi.org\/10.1111\/cen.13796","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1327_CR25","doi-asserted-by":"publisher","first-page":"4776","DOI":"10.1210\/jcem.85.12.7064","volume":"85","author":"CA Stratakis","year":"2000","unstructured":"Stratakis CA et al (2000) Pituitary macroadenoma in a 5-year-old: an early expression of multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 85:4776\u20134780. https:\/\/doi.org\/10.1210\/jcem.85.12.7064","journal-title":"J Clin Endocrinol Metab"},{"key":"1327_CR26","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1210\/jc.2010-1692","volume":"96","author":"S Melmed","year":"2011","unstructured":"Melmed S et al (2011) Diagnosis and treatment of hyperprolactinemia: an endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:273\u2013288. https:\/\/doi.org\/10.1210\/jc.2010-1692","journal-title":"J Clin Endocrinol Metab"},{"key":"1327_CR27","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s11102-005-5087-0","volume":"8","author":"C Yu","year":"2005","unstructured":"Yu C, Wu Z, Gong J (2005) Combined treatment of invasive giant prolactinomas. Pituitary 8:61\u201365. https:\/\/doi.org\/10.1007\/s11102-005-5087-0","journal-title":"Pituitary"},{"key":"1327_CR28","doi-asserted-by":"publisher","first-page":"42","DOI":"10.4158\/EP09221.OR","volume":"16","author":"SV Acharya","year":"2010","unstructured":"Acharya SV, Gopal RA, Menon PS, Bandgar TR, Shah NS (2010) Giant prolactinoma and effectiveness of medical management. Endocr Pract 16:42\u201346. https:\/\/doi.org\/10.4158\/EP09221.OR","journal-title":"Endocr Pract"},{"key":"1327_CR29","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1515\/jpem-2016-0159","volume":"29","author":"J Felker","year":"2016","unstructured":"Felker J, Patterson B, Wrubel D, Janss A (2016) Successful treatment of a child with a prolactin secreting macroadenoma with temozolomide. J Pediatr Endocrinol Metab 29:1413\u20131415. https:\/\/doi.org\/10.1515\/jpem-2016-0159","journal-title":"J Pediatr Endocrinol Metab"},{"key":"1327_CR30","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1530\/EJE-16-0979","volume":"176","author":"H Lasolle","year":"2017","unstructured":"Lasolle H et al (2017) Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas. Eur J Endocrinol 176:769\u2013777. https:\/\/doi.org\/10.1530\/EJE-16-0979","journal-title":"Eur J Endocrinol"},{"key":"1327_CR31","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1111\/j.1365-2265.2012.04373.x","volume":"76","author":"BC Whitelaw","year":"2012","unstructured":"Whitelaw BC et al (2012) Temozolomide in the management of dopamine agonist-resistant prolactinomas. Clin Endocrinol (Oxf) 76:877\u2013886. https:\/\/doi.org\/10.1111\/j.1365-2265.2012.04373.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1327_CR32","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1530\/ERC-15-0320","volume":"22","author":"L Rostomyan","year":"2015","unstructured":"Rostomyan L et al (2015) Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients. Endocr Relat Cancer 22:745\u2013757. https:\/\/doi.org\/10.1530\/ERC-15-0320","journal-title":"Endocr Relat Cancer"},{"key":"1327_CR33","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1159\/000327831","volume":"75","author":"C Personnier","year":"2011","unstructured":"Personnier C et al (2011) Clinical features and treatment of pediatric somatotropinoma: case study of an aggressive tumor due to a new AIP mutation and extensive literature review. Horm Res Paediatr 75:392\u2013402. https:\/\/doi.org\/10.1159\/000327831","journal-title":"Horm Res Paediatr"},{"key":"1327_CR34","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/j.1399-0004.2010.01406.x","volume":"78","author":"CA Stratakis","year":"2010","unstructured":"Stratakis CA et al (2010) The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes. Clin Genet 78:457\u2013463. https:\/\/doi.org\/10.1111\/j.1399-0004.2010.01406.x","journal-title":"Clin Genet"},{"key":"1327_CR35","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1210\/jc.2014-2700","volume":"99","author":"L Katznelson","year":"2014","unstructured":"Katznelson L et al (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99:3933\u20133951. https:\/\/doi.org\/10.1210\/jc.2014-2700","journal-title":"J Clin Endocrinol Metab"},{"key":"1327_CR36","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3389\/fendo.2018.00453","volume":"9","author":"P Gupta","year":"2018","unstructured":"Gupta P et al (2018) Imatinib inhibits GH Secretion from Somatotropinomas. Front Endocrinol (Lausanne) 9:453. https:\/\/doi.org\/10.3389\/fendo.2018.00453","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1327_CR37","doi-asserted-by":"publisher","first-page":"3539","DOI":"10.1210\/jc.2019-00432","volume":"104","author":"P Dutta","year":"2019","unstructured":"Dutta P et al (2019) Surgery, Octreotide, Temozolomide, Bevacizumab, Radiotherapy, and Pegvisomant Treatment of an AIP MutationPositive child. J Clin Endocrinol Metab 104:3539\u20133544. https:\/\/doi.org\/10.1210\/jc.2019-00432","journal-title":"J Clin Endocrinol Metab"},{"key":"1327_CR38","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/1750-1172-6-67","volume":"6","author":"C Nozieres","year":"2011","unstructured":"Nozieres C et al (2011) Sporadic and genetic forms of paediatric somatotropinoma: a retrospective analysis of seven cases and a review of the literature. Orphanet J Rare Dis 6:67. https:\/\/doi.org\/10.1186\/1750-1172-6-67","journal-title":"Orphanet J Rare Dis"},{"key":"1327_CR39","first-page":"1014","volume":"49","author":"AC Crooke","year":"1956","unstructured":"Crooke AC, Purves HD, Russell DS, Thornton KR (1956) Hyalinization and basophil adenomata in the pituitary gland. Proc R Soc Med 49:1014\u20131020","journal-title":"Proc R Soc Med"},{"key":"1327_CR40","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1097\/00000478-200310000-00005","volume":"27","author":"DH George","year":"2003","unstructured":"George DH et al (2003) Crooke\u2019s cell adenoma of the pituitary: an aggressive variant of corticotroph adenoma. Am J Surg Pathol 27:1330\u20131336","journal-title":"Am J Surg Pathol"},{"key":"1327_CR41","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1210\/JC.2015-2493","volume":"100","author":"EH Oldfield","year":"2015","unstructured":"Oldfield EH et al (2015) Crooke\u2019s changes in Cushing\u2019s Syndrome depends on degree of hypercortisolism and individual susceptibility. J Clin Endocrinol Metab 100:3165\u20133171. https:\/\/doi.org\/10.1210\/JC.2015-2493","journal-title":"J Clin Endocrinol Metab"},{"key":"1327_CR42","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1227\/NEU.0000000000000657","volume":"76","author":"A Di Ieva","year":"2015","unstructured":"Di Ieva A et al (2015) Crooke\u2019s cell tumors of the pituitary. Neurosurgery 76:616\u2013622. https:\/\/doi.org\/10.1227\/NEU.0000000000000657","journal-title":"Neurosurgery"},{"key":"1327_CR43","doi-asserted-by":"publisher","unstructured":"Giri D, Roncaroli F, Sinha A, Didi M, Senniappan S (2017) Silent Crooke\u2019s cell corticotroph adenoma of the pituitary gland presenting as delayed puberty. Endocrinol Diabetes Metab Case Rep doi:https:\/\/doi.org\/10.1530\/EDM-16-0153 (2017)","DOI":"10.1530\/EDM-16-0153"},{"key":"1327_CR44","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/bf01407130","volume":"58","author":"IA Felix","year":"1981","unstructured":"Felix IA, Horvath E, Kovacs K (1981) Massive Crooke\u2019s hyalinization in corticotroph cell adenomas of the human pituitary. A histological, immunocytological, and electron microscopic study of three cases. Acta Neurochir (Wien) 58:235\u2013243. https:\/\/doi.org\/10.1007\/bf01407130","journal-title":"Acta Neurochir (Wien)"},{"key":"1327_CR45","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1385\/EP:12:3:329","volume":"12","author":"DJ Holthouse","year":"2001","unstructured":"Holthouse DJ, Robbins PD, Kahler R, Knuckey N, Pullan P (2001) Corticotroph pituitary carcinoma: case report and literature review. Endocr Pathol 12:329\u2013341","journal-title":"Endocr Pathol"},{"key":"1327_CR46","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/eci.12010","volume":"43","author":"GL Kovacs","year":"2013","unstructured":"Kovacs GL et al (2013) ACTH-secreting Crooke cell carcinoma of the pituitary. Eur J Clin Invest 43:20\u201326. https:\/\/doi.org\/10.1111\/eci.12010","journal-title":"Eur J Clin Invest"},{"key":"1327_CR47","doi-asserted-by":"publisher","unstructured":"Jahangiri A et al (2013) A comprehensive long-term retrospective analysis of silent corticotrophic adenomas vs hormone-negative adenomas. Neurosurgery 73, 8\u201317; discussion 17\u201318, doi:https:\/\/doi.org\/10.1227\/01.neu.0000429858.96652.1e","DOI":"10.1227\/01.neu.0000429858.96652.1e"},{"key":"1327_CR48","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s12022-012-9208-9","volume":"23","author":"H Nishioka","year":"2012","unstructured":"Nishioka H, Inoshita N, Sano T, Fukuhara N, Yamada S (2012) Correlation between histological subtypes and MRI findings in clinically nonfunctioning pituitary adenomas. Endocr Pathol 23:151\u2013156. https:\/\/doi.org\/10.1007\/s12022-012-9208-9","journal-title":"Endocr Pathol"},{"key":"1327_CR49","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s11060-017-2520-y","volume":"135","author":"O Cohen-Inbar","year":"2017","unstructured":"Cohen-Inbar O et al (2017) Prognostic significance of corticotroph staining in radiosurgery for non-functioning pituitary adenomas: a multicenter study. J Neurooncol 135:67\u201374. https:\/\/doi.org\/10.1007\/s11060-017-2520-y","journal-title":"J Neurooncol"},{"key":"1327_CR50","doi-asserted-by":"publisher","first-page":"E15","DOI":"10.3171\/2014.11.FOCUS14679","volume":"38","author":"M Zoli","year":"2015","unstructured":"Zoli M et al (2015) ACTH adenomas transforming their clinical expression: report of 5 cases. Neurosurg Focus 38:E15. https:\/\/doi.org\/10.3171\/2014.11.FOCUS14679","journal-title":"Neurosurg Focus"},{"key":"1327_CR51","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1097\/00006123-200009000-00039","volume":"47","author":"BW Scheithauer","year":"2000","unstructured":"Scheithauer BW et al (2000) Clinically silent corticotroph tumors of the pituitary gland. Neurosurgery 47:723\u2013729. https:\/\/doi.org\/10.1097\/00006123-200009000-00039. ; discussion 729\u2013730","journal-title":"Neurosurgery"},{"key":"1327_CR52","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1111\/j.1365-2265.2009.03673.x","volume":"72","author":"HY Cho","year":"2010","unstructured":"Cho HY et al (2010) Silent corticotroph adenomas have unique recurrence characteristics compared with other nonfunctioning pituitary adenomas. Clin Endocrinol (Oxf) 72:648\u2013653. https:\/\/doi.org\/10.1111\/j.1365-2265.2009.03673.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1327_CR53","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/BF00202893","volume":"427","author":"H Oka","year":"1996","unstructured":"Oka H et al (1996) Pituitary choristoma composed of corticotrophs and adrenocortical cells in the sella turcica. Virchows Arch 427:613\u2013617","journal-title":"Virchows Arch"},{"key":"1327_CR54","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1097\/00006123-199803000-00039","volume":"42","author":"CI Coire","year":"1998","unstructured":"Coire CI et al (1998) A composite silent corticotroph pituitary adenoma with interspersed adrenocortical cells: case report. Neurosurgery 42:650\u2013654. https:\/\/doi.org\/10.1097\/00006123-199803000-00039","journal-title":"Neurosurgery"},{"key":"1327_CR55","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1177\/0883073808319078","volume":"23","author":"A Guzel","year":"2008","unstructured":"Guzel A et al (2008) Pituitary carcinoma presenting with multiple metastases: case report. J Child Neurol 23:1467\u20131471. https:\/\/doi.org\/10.1177\/0883073808319078","journal-title":"J Child Neurol"},{"key":"1327_CR56","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s00701-004-0350-0","volume":"146","author":"J Tysome","year":"2004","unstructured":"Tysome J, Gnanalingham KK, Chopra I, Mendoza N (2004) Intradural metastatic spinal cord compression from ACTH-secreting pituitary carcinoma. Acta Neurochir (Wien) 146:1251\u20131254. https:\/\/doi.org\/10.1007\/s00701-004-0350-0","journal-title":"Acta Neurochir (Wien)"},{"key":"1327_CR57","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3171\/jns.1962.19.3.0254","volume":"19","author":"CJ Graf","year":"1962","unstructured":"Graf CJ, Blinderman EE, Terplan KL (1962) Pituitary carcinoma in a child with distant metastases. J Neurosurg 19:254\u2013259. https:\/\/doi.org\/10.3171\/jns.1962.19.3.0254","journal-title":"J Neurosurg"},{"key":"1327_CR58","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s11102-013-0489-x","volume":"17","author":"I Balili","year":"2014","unstructured":"Balili I, Sullivan S, McKeever P, Barkan A (2014) Pituitary carcinoma with endolymphatic sac metastasis. Pituitary 17:210\u2013213. https:\/\/doi.org\/10.1007\/s11102-013-0489-x","journal-title":"Pituitary"},{"key":"1327_CR59","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1530\/EJE-12-0236","volume":"167","author":"L Vroonen","year":"2012","unstructured":"Vroonen L et al (2012) Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. Eur J Endocrinol 167:651\u2013662. https:\/\/doi.org\/10.1530\/EJE-12-0236","journal-title":"Eur J Endocrinol"},{"key":"1327_CR60","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s11060-017-2554-1","volume":"135","author":"MS AbdelBaki","year":"2017","unstructured":"AbdelBaki MS et al (2017) Significant response of pituitary carcinoma to carboplatin, leucovorin and fluorouracil chemotherapy: a pediatric case report and review of the literature. J Neurooncol 135:213\u2013215. https:\/\/doi.org\/10.1007\/s11060-017-2554-1","journal-title":"J Neurooncol"},{"key":"1327_CR61","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1210\/jcem-57-3-649","volume":"57","author":"FE Kaiser","year":"1983","unstructured":"Kaiser FE, Orth DN, Mukai K, Oppenheimer JH (1983) A pituitary parasellar tumor with extracranial metastases and high, partially suppressible levels of adrenocorticotropin and related peptides. J Clin Endocrinol Metab 57:649\u2013653. https:\/\/doi.org\/10.1210\/jcem-57-3-649","journal-title":"J Clin Endocrinol Metab"},{"key":"1327_CR62","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/BF03346909","volume":"20","author":"B Lormeau","year":"1997","unstructured":"Lormeau B, Miossec P, Sibony M, Valensi P, Attali JR (1997) Adrenocorticotropin-producing pituitary carcinoma with liver metastasis. J Endocrinol Invest 20:230\u2013236. https:\/\/doi.org\/10.1007\/BF03346909","journal-title":"J Endocrinol Invest"},{"key":"1327_CR63","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/17446651.2017.1306439","volume":"12","author":"D Iacovazzo","year":"2017","unstructured":"Iacovazzo D, Hernandez-Ramirez LC, Korbonits M (2017) Sporadic pituitary adenomas: the role of germline mutations and recommendations for genetic screening. Expert Rev Endocrinol Metab 12:143\u2013153. https:\/\/doi.org\/10.1080\/17446651.2017.1306439","journal-title":"Expert Rev Endocrinol Metab"},{"key":"1327_CR64","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1530\/EJE-12-0763","volume":"168","author":"T Cuny","year":"2013","unstructured":"Cuny T et al (2013) Genetic analysis in young patients with sporadic pituitary macroadenomas: besides AIP don\u2019t forget MEN1 genetic analysis. Eur J Endocrinol 168:533\u2013541. https:\/\/doi.org\/10.1530\/EJE-12-0763","journal-title":"Eur J Endocrinol"},{"key":"1327_CR65","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1126\/science.276.5311.404","volume":"276","author":"SC Chandrasekharappa","year":"1997","unstructured":"Chandrasekharappa SC et al (1997) Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 276:404\u2013407. https:\/\/doi.org\/10.1126\/science.276.5311.404","journal-title":"Science"},{"key":"1327_CR66","doi-asserted-by":"publisher","first-page":"e1003350","DOI":"10.1371\/journal.pgen.1003350","volume":"9","author":"G Occhi","year":"2013","unstructured":"Occhi G et al (2013) A novel mutation in the upstream open reading frame of the CDKN1B gene causes a MEN4 phenotype. PLoS Genet 9:e1003350. https:\/\/doi.org\/10.1371\/journal.pgen.1003350","journal-title":"PLoS Genet"},{"key":"1327_CR67","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1210\/jcem.87.2.8145","volume":"87","author":"B Verges","year":"2002","unstructured":"Verges B et al (2002) Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab 87:457\u2013465. https:\/\/doi.org\/10.1210\/jcem.87.2.8145","journal-title":"J Clin Endocrinol Metab"},{"key":"1327_CR68","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1097\/PAS.0b013e31815ade45","volume":"32","author":"J Trouillas","year":"2008","unstructured":"Trouillas J et al (2008) Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients. Am J Surg Pathol 32:534\u2013543. https:\/\/doi.org\/10.1097\/PAS.0b013e31815ade45","journal-title":"Am J Surg Pathol"},{"key":"1327_CR69","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s12020-017-1234-4","volume":"58","author":"F Giusti","year":"2017","unstructured":"Giusti F et al (2017) Multiple endocrine neoplasia syndrome type 1: institution, management, and data analysis of a nationwide multicenter patient database. Endocrine 58:349\u2013359. https:\/\/doi.org\/10.1007\/s12020-017-1234-4","journal-title":"Endocrine"},{"key":"1327_CR70","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ando.2012.03.038","volume":"73","author":"B Delemer","year":"2012","unstructured":"Delemer B (2012) MEN1 and pituitary adenomas. Ann Endocrinol (Paris) 73:59\u201361. https:\/\/doi.org\/10.1016\/j.ando.2012.03.038","journal-title":"Ann Endocrinol (Paris)"},{"key":"1327_CR71","doi-asserted-by":"publisher","first-page":"OR24","DOI":"10.1210\/js.2019-OR24-6","volume":"3","author":"L Hern\u00e1ndez-Ram\u00edrez","year":"2019","unstructured":"Hern\u00e1ndez-Ram\u00edrez L, Faucz CF, Lodish FR, Pankratz M, Chittiboina N, Lane P, Kay J, Mills D, Stratakis J (2019) Non-syndromic Cushing\u2019s Disease due to CDKN1B mutations: novel mutations and phenotypic features in a large Pediatric Cohort. J Endocr Soc 3:OR24\u201326","journal-title":"J Endocr Soc"},{"key":"1327_CR72","doi-asserted-by":"publisher","first-page":"3288","DOI":"10.1210\/JC.2015-2015","volume":"100","author":"JM de Laat","year":"2015","unstructured":"de Laat JM et al (2015) Long-term natural course of Pituitary Tumors in patients with MEN1: results from the DutchMEN1 Study Group (DMSG). J Clin Endocrinol Metab 100:3288\u20133296. https:\/\/doi.org\/10.1210\/JC.2015-2015","journal-title":"J Clin Endocrinol Metab"},{"key":"1327_CR73","doi-asserted-by":"publisher","unstructured":"Subasinghe CJ, Somasundaram N, Sivatharshya P, Ranasinghe LD, Korbonits M (2018) Giant Prolactinoma of Young Onset: A Clue to Diagnosis of MEN-1 Syndrome. Case Rep Endocrinol 2875074, doi:https:\/\/doi.org\/10.1155\/2018\/2875074 (2018)","DOI":"10.1155\/2018\/2875074"},{"key":"1327_CR74","doi-asserted-by":"publisher","unstructured":"Gan HW et al (2015) Treatment-resistant pediatric giant prolactinoma and multiple endocrine neoplasia type 1. Int J Pediatr Endocrinol 15, doi:https:\/\/doi.org\/10.1186\/s13633-015-0011-5 (2015)","DOI":"10.1186\/s13633-015-0011-5"},{"key":"1327_CR75","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1046\/j.1365-2265.2001.01031.x","volume":"54","author":"G Kontogeorgos","year":"2001","unstructured":"Kontogeorgos G, Kapranos N, Tzavara I, Thalassinos N, Rologis D (2001) Monosomy of chromosome 11 in pituitary adenoma in a patient with familial multiple endocrine neoplasia type 1. Clin Endocrinol (Oxf) 54:117\u2013120. https:\/\/doi.org\/10.1046\/j.1365-2265.2001.01031.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1327_CR76","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1007\/s12020-017-1322-5","volume":"59","author":"L Vannucci","year":"2018","unstructured":"Vannucci L et al (2018) MEN1 in children and adolescents: data from patients of a regional referral center for hereditary endocrine tumors. Endocrine 59:438\u2013448. https:\/\/doi.org\/10.1007\/s12020-017-1322-5","journal-title":"Endocrine"},{"key":"1327_CR77","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1126\/science.1126100","volume":"312","author":"O Vierimaa","year":"2006","unstructured":"Vierimaa O et al (2006) Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 312:1228\u20131230. https:\/\/doi.org\/10.1126\/science.1126100","journal-title":"Science"},{"key":"1327_CR78","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1210\/jc.2006-2513","volume":"92","author":"AF Daly","year":"2007","unstructured":"Daly AF et al (2007) Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. J Clin Endocrinol Metab 92:1891\u20131896. https:\/\/doi.org\/10.1210\/jc.2006-2513","journal-title":"J Clin Endocrinol Metab"},{"key":"1327_CR79","doi-asserted-by":"publisher","first-page":"E2789","DOI":"10.1210\/jc.2014-2094","volume":"99","author":"C Schofl","year":"2014","unstructured":"Schofl C et al (2014) Frequency of AIP gene mutations in young patients with acromegaly: a registry-based study. J Clin Endocrinol Metab 99:E2789\u20132793. https:\/\/doi.org\/10.1210\/jc.2014-2094","journal-title":"J Clin Endocrinol Metab"},{"key":"1327_CR80","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1111\/j.1365-2265.2008.03266.x","volume":"69","author":"M Georgitsi","year":"2008","unstructured":"Georgitsi M et al (2008) Aryl hydrocarbon receptor interacting protein (AIP) gene mutation analysis in children and adolescents with sporadic pituitary adenomas. Clin Endocrinol (Oxf) 69:621\u2013627. https:\/\/doi.org\/10.1111\/j.1365-2265.2008.03266.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1327_CR81","doi-asserted-by":"publisher","first-page":"E373","DOI":"10.1210\/jc.2009-2556","volume":"95","author":"AF Daly","year":"2010","unstructured":"Daly AF et al (2010) Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J Clin Endocrinol Metab 95:E373\u2013383. https:\/\/doi.org\/10.1210\/jc.2009-2556","journal-title":"J Clin Endocrinol Metab"},{"key":"1327_CR82","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1136\/jmedgenet-2017-104957","volume":"55","author":"F Caimari","year":"2018","unstructured":"Caimari F et al (2018) Risk category system to identify pituitary adenoma patients with AIP mutations. J Med Genet 55:254\u2013260. https:\/\/doi.org\/10.1136\/jmedgenet-2017-104957","journal-title":"J Med Genet"},{"key":"1327_CR83","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1590\/S0004-27302010000800017","volume":"54","author":"LA Naves","year":"2010","unstructured":"Naves LA et al (2010) Aggressive prolactinoma in a child related to germline mutation in the ARYL hydrocarbon receptor interacting protein (AIP) gene. Arq Bras Endocrinol Metabol 54:761\u2013767","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"1327_CR84","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1159\/000488856","volume":"90","author":"K Joshi","year":"2018","unstructured":"Joshi K, Daly AF, Beckers A, Zacharin M (2018) Resistant paediatric somatotropinomas due to AIP mutations: role of Pegvisomant. Horm Res Paediatr 90:196\u2013202. https:\/\/doi.org\/10.1159\/000488856","journal-title":"Horm Res Paediatr"},{"key":"1327_CR85","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1056\/NEJMoa1408028","volume":"371","author":"G Trivellin","year":"2014","unstructured":"Trivellin G et al (2014) Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation. N Engl J Med 371:2363\u20132374. https:\/\/doi.org\/10.1056\/NEJMoa1408028","journal-title":"N Engl J Med"},{"key":"1327_CR86","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1530\/ERC-16-0082","volume":"23","author":"AF Daly","year":"2016","unstructured":"Daly AF et al (2016) Somatic mosaicism underlies X-linked acrogigantism syndrome in sporadic male subjects. Endocr Relat Cancer 23:221\u2013233. https:\/\/doi.org\/10.1530\/ERC-16-0082","journal-title":"Endocr Relat Cancer"},{"key":"1327_CR87","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1530\/ERC-15-0038","volume":"22","author":"A Beckers","year":"2015","unstructured":"Beckers A et al (2015) X-linked acrogigantism syndrome: clinical profile and therapeutic responses. Endocr Relat Cancer 22:353\u2013367. https:\/\/doi.org\/10.1530\/ERC-15-0038","journal-title":"Endocr Relat Cancer"},{"key":"1327_CR88","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1007\/s12020-015-0804-6","volume":"51","author":"LA Naves","year":"2016","unstructured":"Naves LA et al (2016) Aggressive tumor growth and clinical evolution in a patient with X-linked acro-gigantism syndrome. Endocrine 51:236\u2013244. https:\/\/doi.org\/10.1007\/s12020-015-0804-6","journal-title":"Endocrine"},{"key":"1327_CR89","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/ng.3166","volume":"47","author":"M Reincke","year":"2015","unstructured":"Reincke M et al (2015) Mutations in the deubiquitinase gene USP8 cause Cushing\u2019s disease. Nat Genet 47:31\u201338. https:\/\/doi.org\/10.1038\/ng.3166","journal-title":"Nat Genet"},{"key":"1327_CR90","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/cr.2015.20","volume":"25","author":"ZY Ma","year":"2015","unstructured":"Ma ZY et al (2015) Recurrent gain-of-function USP8 mutations in Cushing\u2019s disease. Cell Res 25:306\u2013317. https:\/\/doi.org\/10.1038\/cr.2015.20","journal-title":"Cell Res"},{"key":"1327_CR91","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1210\/jc.2017-00161","volume":"102","author":"FR Faucz","year":"2017","unstructured":"Faucz FR et al (2017) Somatic USP8 gene mutations are a Common cause of Pediatric Cushing Disease. J Clin Endocrinol Metab 102:2836\u20132843. https:\/\/doi.org\/10.1210\/jc.2017-00161","journal-title":"J Clin Endocrinol Metab"},{"key":"1327_CR92","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13802","author":"A Albani","year":"2018","unstructured":"Albani A et al (2018) The USP8 mutational status may predict long-term remission in patients with Cushing\u2019s disease. Clin Endocrinol (Oxf). https:\/\/doi.org\/10.1111\/cen.13802","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1327_CR93","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2019-00697","author":"M Cohen","year":"2019","unstructured":"Cohen M et al (2019) Germline USP8 mutation associated with pediatric cushing disease and other clinical features: a new syndrome. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/jc.2019-00697","journal-title":"J Clin Endocrinol Metab"},{"key":"1327_CR94","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00401-014-1285-z","volume":"128","author":"L de Kock","year":"2014","unstructured":"de Kock L et al (2014) Pituitary blastoma: a pathognomonic feature of germ-line DICER1 mutations. Acta Neuropathol 128:111\u2013122. https:\/\/doi.org\/10.1007\/s00401-014-1285-z","journal-title":"Acta Neuropathol"},{"key":"1327_CR95","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.clp.2017.10.002","volume":"45","author":"C Tatsi","year":"2018","unstructured":"Tatsi C, Stratakis CA (2018) Neonatal cushing syndrome: a rare but potentially devastating disease. Clin Perinatol 45:103\u2013118. https:\/\/doi.org\/10.1016\/j.clp.2017.10.002","journal-title":"Clin Perinatol"},{"key":"1327_CR96","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/nrc3802","volume":"14","author":"WD Foulkes","year":"2014","unstructured":"Foulkes WD, Priest JR, Duchaine TF (2014) DICER1: mutations, microRNAs and mechanisms. Nat Rev Cancer 14:662\u2013672. https:\/\/doi.org\/10.1038\/nrc3802","journal-title":"Nat Rev Cancer"},{"key":"1327_CR97","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1210\/jc.2018-02164","volume":"104","author":"C Tatsi","year":"2019","unstructured":"Tatsi C et al (2019) Large genomic aberrations in Corticotropinomas are Associated with Greater aggressiveness. J Clin Endocrinol Metab 104:1792\u20131801. https:\/\/doi.org\/10.1210\/jc.2018-02164","journal-title":"J Clin Endocrinol Metab"},{"key":"1327_CR98","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1158\/1078-0432.CCR-16-0790","volume":"23","author":"WL Bi","year":"2017","unstructured":"Bi WL et al (2017) Landscape of genomic alterations in Pituitary Adenomas. Clin Cancer Res 23:1841\u20131851. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0790","journal-title":"Clin Cancer Res"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-023-01327-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-023-01327-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-023-01327-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T09:24:19Z","timestamp":1688981059000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-023-01327-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":98,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["1327"],"URL":"https:\/\/doi.org\/10.1007\/s11102-023-01327-2","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"16 May 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Stratakis holds patents on technologies involving PRKAR1A, PDE11A, GPR101 and related genes, and his laboratory has received research funding support by Pfizer Inc., unrelated to this project. Dr. Stratakis currently receives support by ELPEN pharmaceuticals SA, Human Longevity Inc., and has consulted for companies in the last six months on items unrelated to the subject of this report, such as Lundbeck Pharmaceuticals and Sterotherapeutics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Non-applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}